Literature DB >> 8386003

Prevalence of HCV-RNA-positive blood donors and correlation to ELISA and RIBA status.

M da Silva Cardoso1, K Koerner, S Epple, B Kubanek.   

Abstract

In Germany, transmission of hepatitis C virus by blood transfusion is prevented by screening the donations for anti-HCV and ALT. The specificity of the anti-HCV screening in low seroprevalence populations has been questioned. In order to evaluate this screening policy we wanted to estimate the prevalence of viremic and potentially infectious donors by the HCV-RNA polymerase chain reaction (PCR) in our donor population of southern Germany. Donors (n = 301) were divided into four subgroups according to anti-HCV status and ALT levels. HCV sequences were detected by nested PCR, using primers for the most conserved region of the viral genome. The recombinant immunoblot assay (RIBA-4) was applied to the same samples. PCR detected 4.2% HCV-RNA carriers in the subgroup anti-HCV-/ALT-; 3% in the subgroup anti-HCV-/ALT+; 19.4% in the subgroup anti-HCV+/ALT-; and 59.4% in the subgroup anti-HCV+/ALT+. It was concluded that, on the one hand, the lack of specificity of the anti-HCV ELISA gives rise to many false-positive results; on the other hand, a minority of infected donations will not be detected by the screening procedure. ALT in conjunction with anti-HCV improves the quality of screening for potentially infectious donors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8386003     DOI: 10.1007/bf01697626

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  23 in total

1.  Confirmation of hepatitis C virus positive blood donors by immunoblotting and polymerase chain reaction.

Authors:  H De Beenhouwer; H Verhaert; H Claeys; C Vermylen
Journal:  Vox Sang       Date:  1992       Impact factor: 2.144

2.  [Experiences with a simple microtiter plate technique for GPT screening of blood donors].

Authors:  T Dengler; S Kellner; G Fürst
Journal:  Infusionsther Transfusionsmed       Date:  1992-04

3.  Serological responses to infection with three different types of hepatitis C virus.

Authors:  S W Chan; P Simmonds; F McOmish; P L Yap; R Mitchell; B Dow; E Follett
Journal:  Lancet       Date:  1991-11-30       Impact factor: 79.321

4.  Hepatitis C virus RNA in symptomless donors implicated in post-transfusion non-A, non-B hepatitis.

Authors:  A R Zanetti; E Tanzi; G Zehender; E Magni; C Incarbone; A Zonaro; D Primi; E Cariani
Journal:  Lancet       Date:  1990-08-18       Impact factor: 79.321

5.  Hepatitis C virus RNA in blood donor sera detected by the polymerase chain reaction: comparison with supplementary hepatitis C antibody assays.

Authors:  A Widell; A S Månsson; G Sundström; B G Hansson; E Nordenfelt
Journal:  J Med Virol       Date:  1991-12       Impact factor: 2.327

6.  Recombinant immunoblot assay first and second generations on 732 blood donors reactive for antibodies to hepatitis C virus by ELISA. The Hepatitis Study Group of the French Society of Blood Transfusion.

Authors:  A M Couroucé; C Janot
Journal:  Vox Sang       Date:  1991       Impact factor: 2.144

7.  Investigating the presence of HIV sequences and the distribution of virological markers in hemophiliacs and their sexual partners.

Authors:  M da S Cardoso; S Epple; K Koerner; B Kubanek; D Ellbrück; E Seifried
Journal:  Ann Hematol       Date:  1991-12       Impact factor: 3.673

8.  Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis.

Authors:  H J Alter; R H Purcell; J W Shih; J C Melpolder; M Houghton; Q L Choo; G Kuo
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

9.  Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection.

Authors:  M J Alter; S C Hadler; F N Judson; A Mares; W J Alexander; P Y Hu; J K Miller; L A Moyer; H A Fields; D W Bradley
Journal:  JAMA       Date:  1990-11-07       Impact factor: 56.272

10.  Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay.

Authors:  C L Van der Poel; H T Cuypers; H W Reesink; A J Weiner; S Quan; R Di Nello; J J Van Boven; I Winkel; D Mulder-Folkerts; P J Exel-Oehlers
Journal:  Lancet       Date:  1991-02-09       Impact factor: 79.321

View more
  7 in total

1.  Analysing the sequence diversity of the 5' NC-region of HCV-isolates found in southern Germany.

Authors:  M Da Silva Cardoso; S Epple; K Koerner; B Kubanek
Journal:  Eur J Epidemiol       Date:  1994-10       Impact factor: 8.082

2.  Human monoclonal antibodies for the immunological characterization of a highly conserved protein domain of the hepatitis C virus glycoprotein E1.

Authors:  K Siemoneit; M da S Cardoso; K Koerner; A Wölpl; B Kubanek
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

3.  Isotype-specific immune response to a single hepatitis C virus core epitope defined by a human monoclonal antibody: diagnostic value and correlation to PCR.

Authors:  K Siemoneit; M da Silva Cardoso; A Wölpl; S Epple; H Wintersinger; K Koerner; B Kubanek
Journal:  Ann Hematol       Date:  1994-09       Impact factor: 3.673

4.  The serology of hepatitis C virus (HCV) infection: antibody crossreaction in the hypervariable region 1.

Authors:  M da Silva Cardoso; K Siemoneit; V Nemecek; S Epple; K Koerner; B Kubanek
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

5.  Risk of hepatitis C virus (HCV) transmission by anti-HCV-negative blood components in Austria and Germany.

Authors:  J Riggert; D W Schwartz; A Uy; G Simson; F Jelinek; H Fabritz; W R Mayr; M Köhler
Journal:  Ann Hematol       Date:  1996-01       Impact factor: 3.673

6.  Hepatitis C virus (HCV)-specific in vitro antibody secretion by peripheral blood lymphocytes: correlation with progression of disease and HCV RNA in HCV antibody-positive patients.

Authors:  J Ducos; A M Bianchi-Mondain; M Francois; M Boisset; J P Vendrell; F Barin; A Serre; D Larrey
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

7.  Low Specificity of the Third Generation Elisa for HCV Detection in Voluntary Blood Donors in India.

Authors:  V Thakur; R C Guptan; V Arankale; S K Sarin
Journal:  EJIFCC       Date:  2003-04-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.